{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013037","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.878596+00:00","generated_at":"2026-05-15T04:48:58.902452+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CervoMed: neflamapimod increases basal forebrain volume in DLB Phase 2b MRI analysis","bullets":["At week 16, right BF volume increased 3.5% with neflamapimod vs -4.2% with placebo (p=0.028).","Right BF to DMN functional connectivity improved 46% during 32-week extension (p=0.014).","Improvement in functional connectivity correlated with CDR-SB reduction (p=0.027, r²=0.43).","Company plans to start Phase 3 trial in DLB later this year, subject to financing.","Data presented at 2026 AAN Annual Meeting by Amsterdam UMC; blinded analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013037","json":"https://secwatch.observer/filing/0001437749-26-013037.json","markdown":"https://secwatch.observer/filing/0001437749-26-013037.md","text":"https://secwatch.observer/filing/0001437749-26-013037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926013037/0001437749-26-013037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926013037/crvo20260422_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:48:58.902452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}